VCEL (Vericel) GF Value Rank : 7 (As of Apr. 23, 2025)

View and export this data going back to 1997. Start your Free Trial

What is Vericel GF Value Rank?

Vericel has the GF Value Rank of 7.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Vericel's GF Value Rank

For the Biotechnology subindustry, Vericel's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vericel's GF Value Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vericel's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Vericel's GF Value Rank falls into.

Save Embed

;

Save Embed

;

Vericel GF Value Rank Related Terms

Thank you for viewing the detailed overview of Vericel's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Vericel Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vericel Corp (NAS:VCEL) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

ATQP:Germany ATQP:Germany

Address

64 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.vcel.com

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Executives

Dominick Colangelo	director, officer: President and CEO	1000 WINTER ST., SUITE 2200, WALTHAM MA 02451
Jonathan Siegal	officer: Principal Accounting Officer	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Sean C. Flynn	officer: SVP, General Counsel	C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Kevin F Mclaughlin	director	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Zerbe Robert L Md	director
Paul K Wotton	director	C/O ANTARES PHARMA, INC., 707 EAGLEVIEW BOULEVARD, SUITE 414, EXTON PA 19341
Jonathan Mark Hopper	officer: Chief Medical Officer	64 SIDNEY STREET, CAMBRIDGE MA 02139
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421
Mara Joseph Anthony Jr	officer: Chief Financial Officer	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Michael Halpin	officer: Chief Operating Officer	C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Lisa Wright	director	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Sandra Pennell	officer: VP and Corporate Controller	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Gerard J Michel	officer: CFO & VP , Corp. Development	420 CHIPETA WAY, SALT LAKE CITY UT 84108
Daniel Orlando	officer: Chief Operating Officer	P.O. BOX 376, ANN ARBOR MI 48105
Alan L Rubino	director	PO BOX 376, LOBBY L., ANN ARBOR MI 48105